文献速递白血病造血干细胞移植与细胞治疗

髓系细胞靶向miR-146a模拟物抑制NF-κB驱动的炎症与白血病进展

Myeloid cell-targeted miR-146a mimic inhibits NF-κB-driven inflammation and leukemia progression in vivo.
PubMed 文献 · Blood · 2020-01-01

本研究开发了一种偶联于清道夫受体/Toll样受体9激动剂的miR-146a模拟物寡核苷酸(C-miR146a),可选择性靶向髓系细胞并抑制NF-κB活化。在miR-146a缺陷小鼠中,静脉注射C-miR146a减轻了髓系增殖和对细菌攻击的超敏反应;在CAR-T诱导的细胞因子释放综合征模型中减轻严重炎症;在B细胞淋巴瘤异种移植模型中减少IL-1和IL-6释放而不影响CAR-T抗肿瘤活性;在白血病细胞中诱导细胞毒性并抑制播散性HL-60白血病进展。

要点

  • C-miR146a可选择性递送至髓系细胞和白血病细胞,降低IRAK1和TRAF6表达,阻断NF-κB活化。
  • 在CAR-T相关细胞因子释放综合征模型中,C-miR146a减轻严重炎症而不影响CD19 CAR-T抗肿瘤活性。
  • 重复静脉注射C-miR146a可抑制NF-κB靶基因表达,延缓播散性HL-60白血病进展。

核心结论

  • 髓系细胞靶向的miR-146a模拟物C-miR146a可抑制NF-κB驱动的炎症和白血病进展,具有治疗炎症及骨髓增殖性疾病的潜力。

研究设计与样本

  • 临床前研究:使用miR-146a缺陷小鼠、CAR-T诱导的细胞因子释放综合征模型、异种移植B细胞淋巴瘤模型及人白血病细胞系(MDSL、HL-60、MV4-11)。
  • 利用癌症基因组图谱(TCGA)急性髓系白血病数据集分析miR-146a水平与NF-κB相关基因及患者生存的相关性。

主要发现

  • C-miR146a可快速内化并递送至靶髓系细胞和白血病细胞质,降低IRAK1和TRAF6表达,阻断NF-κB活化。
  • 静脉注射C-miR146a至miR-146a缺陷小鼠可防止髓系细胞过度NF-κB活化,减轻髓系增殖和对细菌攻击的超敏反应。
  • 在CAR-T诱导的细胞因子释放综合征临床相关模型中,C-miR146a减轻严重炎症。
  • 在异种移植B细胞淋巴瘤模型中,全身给予C-miR146a减少人单核细胞依赖性IL-1和IL-6释放,且不影响CD19特异性CAR-T抗肿瘤活性。
  • TCGA急性髓系白血病数据显示miR-146a水平与NF-κB相关基因及患者生存呈负相关;C-miR146a在体外对MDSL、HL-60和MV4-11白血病细胞诱导细胞毒性,重复静脉给药抑制NF-κB靶基因表达并阻止播散性HL-60白血病进展。

关键数值与推荐

  • C-miR146a为miR-146a模拟物寡核苷酸偶联清道夫受体/Toll样受体9激动剂,可选择性靶向髓系细胞。
  • C-miR146a降低经典miR-146a靶点IRAK1和TRAF6表达,阻断NF-κB活化。

临床怎么用

  • C-miR146a作为一种髓系细胞选择性NF-κB抑制剂,可能用于治疗炎症性疾病和骨髓增殖性疾病。
  • 在CAR-T治疗相关细胞因子释放综合征中,C-miR146a可减轻炎症而不影响CAR-T抗肿瘤活性。
  • 对于NF-κB驱动的髓系白血病,靶向递送miR-146a模拟物可能成为潜在治疗策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

NF-κB is a key regulator of inflammation and cancer progression, with an important role in leukemogenesis. Despite its therapeutic potential, targeting NF-κB using pharmacologic inhibitors has proven challenging. Here, we describe a myeloid cell-selective NF-κB inhibitor using an miR-146a mimic oligonucleotide conjugated to a scavenger receptor/Toll-like receptor 9 agonist (C-miR146a). Unlike an unconjugated miR146a, C-miR146a was rapidly internalized and delivered to the cytoplasm of target myeloid cells and leukemic cells. C-miR146a reduced expression of classic miR-146a targets (IRAK1 and TRAF6), thereby blocking activation of NF-κB in target cells. IV injections of C-miR146a mimic to miR-146a-deficient mice prevented excessive NF-κB activation in myeloid cells, and thus alleviated myeloproliferation and mice hypersensitivity to bacterial challenge. Importantly, C-miR146a showed efficacy in dampening severe inflammation in clinically relevant models of chimeric antigen receptor (CAR) T-cell-induced cytokine release syndrome. Systemic administration of C-miR146a oligonucleotide alleviated human monocyte-dependent release of IL-1 and IL-6 in a xenotransplanted B-cell lymphoma model without affecting CD19-specific CAR T-cell antitumor activity. Beyond anti-inflammatory functions, miR-146a is a known tumor suppressor commonly deleted or expressed at reduced levels in human myeloid leukemia. Using The Cancer Genome Atlas acute myeloid leukemia data set, we found an inverse correlation of miR-146a levels with NF-κB-related genes and with patient survival. Correspondingly, C-miR146a induced cytotoxic effects in human MDSL, HL-60, and MV4-11 leukemia cells in vitro. The repeated IV administration of C-miR146a inhibited expression of NF-κB target genes and thereby thwarted progression of disseminated HL-60 leukemia. Our results show the potential of using myeloid cell-targeted miR-146a mimics for the treatment of inflammatory and myeloproliferative disorders.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Su YL, Wang X, Mann M, et al. Myeloid cell-targeted miR-146a mimic inhibits NF-κB-driven inflammation and leukemia progression in vivo. Blood. 2020. PMID: 31805184. doi:10.1182/blood.2019002045

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。